J Quan, PH Tan, A MacDonald, PJ Friend: Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges. In: Expert Opin Biol Ther. 8. Jahrgang, Nr.11, November 2008, S.1705–1719, doi:10.1517/14712598.8.11.1705, PMID 18847306.
HJ Yuasa, M Takubo, A Takahashi, T Hasegawa, H Noma, T Suzuki: Evolution of vertebrate indoleamine 2,3-dioxygenases. In: J. Mol. Evol. 65. Jahrgang, Nr.6, Dezember 2007, S.705–714, doi:10.1007/s00239-007-9049-1, PMID 18026683.
TJ Connor, N Starr, JB O’Sullivan, A. Harkin: Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma? In: Neurosci Lett., 2008 Aug 15;441(1), S. 29–34. doi:10.1016/j.neulet.2008.06.007. Epub 2008 Jun 7.
N Müller, D Krause, E Weidinger, M Schwarz: Immunological treatment options for schizophrenia. In: Fortschr Neurol Psychiatr., 2014 Apr;82(4), S. 210–219, doi:10.1055/s-0033-1355776.
A Buness, A Roth, A Herrmann, O Schmitz, H Kamp et al.: Identification of Metabolites, Clinical Chemistry Markers and Transcripts Associated with Hepatotoxicity. In: PLoS ONE 9, 2014, S. e97249. doi:10.1371/journal.pone.0097249
JB Katz, AJ Muller, GC Prendergast: Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. In: Immunol. Rev. 222. Jahrgang, April 2008, S.206–221, doi:10.1111/j.1600-065X.2008.00610.x, PMID 18364004.
AJ Muller, MD Sharma, PR Chandler et al.: Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. In: Proc. Natl. Acad. Sci. U.S.A. 105. Jahrgang, Nr.44, November 2008, S.17073–17078, doi:10.1073/pnas.0806173105, PMID 18952840.
YI Jeong, SW Kim, ID Jung et al.: Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the JAK-PKC-delta -STAT1 signalling pathway in IFN-gamma -stimulated murine dendritic cells. In: J. Biol. Chem. Dezember 2008, doi:10.1074/jbc.M807328200, PMID 19075017.
K Schroecksnadel, C Winkler, ER Werner et al.: Interferon-gamma-mediated pathways and in vitro PBMC proliferation in HIV-infected patients. In: Biol. Chem. November 2008, doi:10.1515/BC.2009.018, PMID 19040353.
JC O’Connor, MA Lawson, C André et al.: Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. In: Mol. Psychiatry. Januar 2008, doi:10.1038/sj.mp.4002148, PMID 18195714.
S Lob, A Konigsrainer, R Schafer, HG Rammensee, G Opelz, P Terness: Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. In: Blood. 111. Jahrgang, Nr.4, Februar 2008, S.2152–2154, doi:10.1182/blood-2007-10-116111, PMID 18045970.
HC Brastianos, E Vottero, BO Patrick et al.: Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. In: J. Am. Chem. Soc. 128. Jahrgang, Nr.50, Dezember 2006, S.16046–16047, doi:10.1021/ja067211+, PMID 17165752.
S Kumar, WP Malachowski, JB DuHadaway et al.: Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. In: J. Med. Chem. 51. Jahrgang, Nr.6, März 2008, S.1706–1718, doi:10.1021/jm7014155, PMID 18318466.
elsevier.com
linkinghub.elsevier.com
WD Billington: The immunological problem of pregnancy: 50 years with the hope of progress. A tribute to Peter Medawar. In: J. Reprod. Immunol. 60. Jahrgang, Nr.1, Oktober 2003, S.1–11, PMID 14568673 (elsevier.com).
nbn-resolving.de
Erik Kwidzinski: Beteiligung der Indolamin 2,3-Dioxygenase (IDO) an Immunregulation des zentralen Nervensystems. Dissertation, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, publiziert am 13. Februar 2006, urn:nbn:de:kobv:11-10059777
J Quan, PH Tan, A MacDonald, PJ Friend: Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges. In: Expert Opin Biol Ther. 8. Jahrgang, Nr.11, November 2008, S.1705–1719, doi:10.1517/14712598.8.11.1705, PMID 18847306.
HJ Yuasa, M Takubo, A Takahashi, T Hasegawa, H Noma, T Suzuki: Evolution of vertebrate indoleamine 2,3-dioxygenases. In: J. Mol. Evol. 65. Jahrgang, Nr.6, Dezember 2007, S.705–714, doi:10.1007/s00239-007-9049-1, PMID 18026683.
ER Werner, G Werner-Felmayer: Substrate and cofactor requirements of indoleamine 2,3-dioxygenase in interferon-gamma-treated cells: utilization of oxygen rather than superoxide. In: Curr. Drug Metab. 8. Jahrgang, Nr.3, April 2007, S.201–203, PMID 17430107.
W Chen, X Liang, AJ Peterson, DH Munn, BR Blazar: The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. In: J. Immunol. 181. Jahrgang, Nr.8, Oktober 2008, S.5396–5404, PMID 18832696.
JB Katz, AJ Muller, GC Prendergast: Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. In: Immunol. Rev. 222. Jahrgang, April 2008, S.206–221, doi:10.1111/j.1600-065X.2008.00610.x, PMID 18364004.
AJ Muller, MD Sharma, PR Chandler et al.: Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. In: Proc. Natl. Acad. Sci. U.S.A. 105. Jahrgang, Nr.44, November 2008, S.17073–17078, doi:10.1073/pnas.0806173105, PMID 18952840.
WD Billington: The immunological problem of pregnancy: 50 years with the hope of progress. A tribute to Peter Medawar. In: J. Reprod. Immunol. 60. Jahrgang, Nr.1, Oktober 2003, S.1–11, PMID 14568673 (elsevier.com).
DH Munn, M Zhou, JT Attwood et al.: Prevention of allogeneic fetal rejection by tryptophan catabolism. In: Science. 281. Jahrgang, Nr.5380, August 1998, S.1191–1193, PMID 9712583.
YI Jeong, SW Kim, ID Jung et al.: Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the JAK-PKC-delta -STAT1 signalling pathway in IFN-gamma -stimulated murine dendritic cells. In: J. Biol. Chem. Dezember 2008, doi:10.1074/jbc.M807328200, PMID 19075017.
K Schroecksnadel, C Winkler, ER Werner et al.: Interferon-gamma-mediated pathways and in vitro PBMC proliferation in HIV-infected patients. In: Biol. Chem. November 2008, doi:10.1515/BC.2009.018, PMID 19040353.
JC O’Connor, MA Lawson, C André et al.: Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. In: Mol. Psychiatry. Januar 2008, doi:10.1038/sj.mp.4002148, PMID 18195714.
S Lob, A Konigsrainer, R Schafer, HG Rammensee, G Opelz, P Terness: Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. In: Blood. 111. Jahrgang, Nr.4, Februar 2008, S.2152–2154, doi:10.1182/blood-2007-10-116111, PMID 18045970.
HC Brastianos, E Vottero, BO Patrick et al.: Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. In: J. Am. Chem. Soc. 128. Jahrgang, Nr.50, Dezember 2006, S.16046–16047, doi:10.1021/ja067211+, PMID 17165752.
S Kumar, WP Malachowski, JB DuHadaway et al.: Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. In: J. Med. Chem. 51. Jahrgang, Nr.6, März 2008, S.1706–1718, doi:10.1021/jm7014155, PMID 18318466.